Herring, W. L. Et Al. 2022. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. PharmacoEconomics , vol.40, no.3 , 323-339.

Herring, W. L., Zhang, Y., Tempest, M., Pearson, I., Freudensprung, U., Acosta, C., ... Dort, T.(2022). Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. PharmacoEconomics , vol.40, no.3, 323-339.

Herring, William Et Al. "Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom," PharmacoEconomics , vol.40, no.3, 323-339, 2022

Herring, William L. Et Al. "Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom." PharmacoEconomics , vol.40, no.3, pp.323-339, 2022

Herring, W. L. Et Al. (2022) . "Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom." PharmacoEconomics , vol.40, no.3, pp.323-339.

@article{article, author={William L. Herring Et Al. }, title={Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom}, journal={PharmacoEconomics}, year=2022, pages={323-339} }